PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 

Daedal Research

Press Release


Receive press releases from Daedal Research: By Email RSS Feeds:
Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-19) – New Report by Daedal Research

The report titled “Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-2019)” provides an insight into migraine drugs with a special focus on Triptans.

New Delhi, India, July 09, 2014 --(PR.com)-- The report also includes the market value, segmentation, types of diagnosis and treatment for migraine. It also discusses key growth drivers and upcoming trends of the market. Further, key manufacturers of anti-migraine drugs like Endo International Inc, Imapc Laboratories, GlaxoSmithKline and Pfizer Inc. are profiled in the report.

Segments Coverage

- Triptans
- Ergot Alkaloids

Company Coverage

- Endo International Inc.
- IMPAX Laboratories Inc.
- GlaxoSmith Kline (GSK)
- Pfizer Inc.

Executive Summary

Migraine, a condition of recurring headaches and is accompanied by symptoms like nausea, vomiting, dizziness and sensitivity to light and noise ranks among the World’s Top 20 disabling medical illnesses. It is anticipated that launches of many generic migraine drugs over the next several years will steadily increase diagnosis and drug-treatment rates, leading to sustained annual global growth of anti-migraine drugs market. Other factors contributing to the growth of these drugs include awareness among the people about proper diagnosis and treatment of migraine, rise in medical expenditures and new drugs launches.

Acute migraine treatment market is dominant by Triptans and most of them are available as pills. Triptans like Sumatriptan and Zolmitriptan are also available as nasal sprays whereas rizatriptan and zolmitriptan are available as tablets that dissolve in the mouth. In the next 5-10 years, the cost of migraine drugs is anticipated to decline due to many generic entrants as most of them are losing their patents. Growing awareness of migraine in the emerging countries and fall in prices will facilitate the growth of anti-migraine drugs market. In addition, with the development of new treatment therapies like calcitonin gene-related peptides (CGRP) receptor antagonist and BOTOX the demand for anti-migraine drugs is anticipated to grow further.

The US is the largest market for anti-migraine drugs and there are number of companies that manufacture these drugs. Major companies include Impax, Endo Pharmaceuticals, Pfizer, GlaxoSmith Kline, Nautilus and Allergan.

For further details, kindly visit :

Rajeev Kumar
(Business Development Manager)
Address: 36 SFS Flats
Paschim Vihar
New Delhi-110063
Mobile: +91-8743975789
Tel: +91-120-4553017
Contact Information
Daedal Research
Satyam Singh
+91-8743975789
Contact
http://www.daedal-research.com/global-anti-migraine-drugs-market-trends-and-opportunities-2014-192
Rajeev Kumar
(Business Development Manager)
http://www.daedal-research.com/global-anti-migraine-drugs-market-trends-and-opportunities-2014-192

Address: 36 SFS Flats
Paschim Vihar
New Delhi-110063
Tel: +91-120-4553017

Click here to view the list of recent Press Releases from Daedal Research
Promote Your Business